From the Department of Facial Plastic and Reconstructive Surgery, Eye and ENT Hospital of Fudan University, Shanghai 200031, China.
Ann Plast Surg. 2021 Nov 1;87(5):523-527. doi: 10.1097/SAP.0000000000002867.
This study aims to evaluate the clinical effect of modified maximal levator palpebrae superioris shortening method for severe congenital ptosis.
A retrospective case series was performed including 66 eyes from 62 patients who underwent modified maximal levator palpebrae superioris shortening surgery to treat severe congenital ptosis between February 2015 and November 2018. Preoperative and postoperative margin reflex distance 1 and levator muscle function were recorded. The surgical results were graded as good, satisfied, and poor for functional and cosmetic improvement of the eyelids, and the incidence of complications was also documented.
The mean patient age at the time of surgery was 4.6 ± 1.8 years (2-9 years), and the mean follow-up time was 36.3 ± 14.1 (12-55 months). A mean significant improvement in margin reflex distance 1 and levator function after operation was noted (P < 0.01). The eyelid height and symmetry were satisfied in 59 patients, with success rate of 95.2%. For the patients in the levator function (≤2 mm) group, the success rate was 87.5%. Moreover, the levator function (≤2 mm) group had a higher rate of poor results than levator function (2-4 mm) group (12.5% vs 2.2%). Overcorrection (6.5%) and eyelid fold deformity (11.3%) were the most frequent postoperative complications.
Modified maximal levator palpebrae superioris shortening was effective and endurable in the treatment of severe congenital ptosis with poor levator function, including in patients whose levator function was less than 2 mm.
本研究旨在评估改良最大提上睑肌缩短术治疗重度先天性上睑下垂的临床效果。
回顾性病例系列研究,纳入 2015 年 2 月至 2018 年 11 月期间 62 例(66 眼)重度先天性上睑下垂患者,行改良最大提上睑肌缩短术,记录术前、术后的上睑缘移动距离 1(MRD1)和提上睑肌功能,并对手术效果进行分级,以评估眼睑功能和美容改善的效果,同时记录并发症的发生情况。
患者的平均手术年龄为 4.6±1.8 岁(29 岁),平均随访时间为 36.3±14.1 个月(1255 个月)。术后 MRD1 和提上睑肌功能均有显著改善(P<0.01)。59 例患者的眼睑高度和对称性满意,成功率为 95.2%。提上睑肌功能(≤2mm)组的成功率为 87.5%。此外,提上睑肌功能(≤2mm)组的不良结果发生率高于提上睑肌功能(2~4mm)组(12.5%比 2.2%)。术后最常见的并发症为过矫(6.5%)和眼睑褶皱畸形(11.3%)。
改良最大提上睑肌缩短术对于提上睑肌功能较差(包括提上睑肌功能<2mm)的重度先天性上睑下垂患者是一种有效且持久的治疗方法。